Talquetamab Infection Burden: Half Any-Grade, One-Fifth Severe
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low
Huang ZY, Wu W, Luo G, et al.
Sep 3, 2026 · Published in: Frontiers in Immunology
Also in Infectious Disease / Antimicrobials
Talquetamab raises infection concerns in RRMM patients.
Cisplatin vs Carboplatin: Only Two Comparisons Reach High-Certainty Evidence
Analysis Oncology Pharmacy Confirmatory Grade: Low
Jiménez-Labaig P, Mirallas O, Pereira F, et al.
Sep 1, 2026 · Published in: JAMA Netw Open
Cisplatin outperforms carboplatin in certain cancers but with higher toxicity.
Two-Sample 3-and-7-Hour Schedule Optimizes Once-Daily Busulfan TDM
Analysis Pharmacokinetics / TDM Confirmatory Grade: Low
Tan Z, Achini-Gutzwiller FR, Lankester AC, et al.
Sep 1, 2026 · Published in: Journal of Clinical Pharmacology
Also in Oncology
Enhance busulfan dosing with a precise two-sample strategy.
Pharmacist-Integrated Multidisciplinary Care in Pregnancy-Associated Breast Cancer
Analysis Oncology Pharmacy Hypothesis-generating Grade: Very Low
Liu H, Jin J, Deng Y, et al.
Aug 28, 2026 · Published in: Frontiers in Oncology
Also in Women's Health / Reproductive
Pharmacists enhance pregnancy-related chemotherapy care for breast cancer.
EMERALD-3: STRIDE Plus Lenvatinib and TACE Extends PFS, Not Yet OS
Analysis Oncology Pharmacy Hypothesis-generating Grade: Moderate
Kudo M, Abou-Alfa GK, Ren Z, et al.
Aug 24, 2026 · Published in: The Lancet. Oncology
Also in Gastroenterology / Hepatology
Combination therapy advances progression-free survival in liver cancer.
Fragile Efficacy Signals Underlie DOACs for Cancer-Associated VTE
Analysis Anticoagulation / Hematology Confirmatory Grade: Moderate
Zuin M, Becattini C, Vedovati MC, et al.
Aug 20, 2026 · Published in: Research and Practice in Thrombosis and Haemostasis
Also in Oncology
DOACs for cancer thrombosis: Efficacy vs. bleeding risk.
Adding Camrelizumab to TACE Plus Donafenib in PVTT-Positive HCC
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low
Zhang Q, Qing H, Lei Z, et al.
Aug 20, 2026 · Published in: Frontiers in Immunology
Also in Gastroenterology / Hepatology
Transarterial chemoembolization with donafenib and camrelizumab may extend survival in challenging liver cancer cases.
Dual-level network meta-analysis maps first-line immunotherapy strategies in HCC
Analysis Oncology Pharmacy Confirmatory Grade: Moderate
Zhang Q, Hu Y, Ge Y, et al.
Aug 20, 2026 · Published in: Frontiers in Immunology
Determining the best immunotherapy strategy for advanced hepatocellular carcinoma remains a challenging decision for clinicians.
SCLC 2026: Consolidation Durvalumab, Maintenance Lurbinectedin, and Tarlatamab Reshape Care
Analysis Oncology Pharmacy Confirmatory Grade: Moderate
Lalla M, Dhillon P, Polat BE, et al.
Aug 20, 2026 · Published in: Lung
New therapeutic advances redefine small cell lung cancer management.
Perioperative Enfortumab Vedotin plus Pembrolizumab Cost-Effective in Cisplatin-Ineligible MIBC
Analysis Oncology Pharmacy Confirmatory Grade: Low
Hill-McManus D, Lai Y, Bensimon AG, et al.
Aug 18, 2026 · Published in: Journal of Medical Economics
Pembrolizumab plus enfortumab vedotin stands out as cost-effective for bladder cancer.
Metronomic Doxorubicin Plus Low-Dose Radiation in Preclinical Breast Cancer
Analysis Oncology Pharmacy Hypothesis-generating Grade: Very Low
Abdelrahman IY, Saif-Elnasr M, Attia ZR, et al.
Aug 13, 2026 · Published in: Cell Biochemistry and Function
Metronomic doxorubicin plus low-dose radiation shows promise for breast cancer.
Erdafitinib Wins Traditional Approval for FGFR3-Altered Urothelial Cancer
Analysis Oncology Pharmacy Confirmatory Grade: Moderate
Maguire WF, Chang E, Mulkey F, et al.
Aug 12, 2026 · Published in: Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Erdafitinib boosts survival in advanced FGFR3-altered bladder cancer.
NTM in Oncology: Dual Beta-Lactam Signals Warrant Study
Analysis Infectious Disease / Antimicrobials Hypothesis-generating Grade: Very Low
Pasikhova Y, Snyder M, Morrison A, et al.
Aug 8, 2026 · Published in: Open Forum Infectious Diseases
Also in Oncology
NTM infections in cancer patients demand complex treatment approaches.
Causal Methods Dissolve Apparent Harm of Ibrutinib Dose Modification
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low
Dang V, Muluneh B, Chen K, et al.
Aug 7, 2026 · Published in: Clinical Pharmacology and Therapeutics
Ibrutinib dose changes in leukemia might not impact survival as once thought.
Intracranial B7-H3 CAR-T Shows Early Promise in Recurrent Glioblastoma
Analysis Oncology Pharmacy Hypothesis-generating Grade: Very Low
Zhang Y, Chi X, Feng R, et al.
Aug 7, 2026 · Published in: Nature Medicine
CAR-T cell therapy offers new hope for recurrent glioblastoma.